Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $25.51 in the prior trading day, Progyny Inc (NASDAQ: PGNY) closed at $25.8, up 1.14%. In other words, the price has increased by $1.14 from its previous closing price. On the day, 1.0 million shares were traded. PGNY stock price reached its highest trading level at $25.96 during the session, while it also had its lowest trading level at $25.1385.
Ratios:
Our goal is to gain a better understanding of PGNY by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.44 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.50. For the most recent quarter (mrq), Quick Ratio is recorded 2.96 and its Current Ratio is at 2.96. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $29. On November 12, 2025, KeyBanc Capital Markets Upgraded its rating to Overweight which previously was Sector Weight but kept the price unchanged to $30. Leerink Partners Upgraded its Market Perform to Outperform on July 08, 2025, while the target price for the stock was maintained at $28.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 ’25 when Livingston Mark S. sold 459 shares for $25.50 per share. The transaction valued at 11,704 led to the insider holds 46,983 shares of the business.
Livingston Mark S. bought 459 shares of PGNY for $11,704 on Dec 11 ’25. On Dec 04 ’25, another insider, Swartz Allison, who serves as the EVP, GC of the company, sold 530 shares for $24.59 each. As a result, the insider received 13,033 and left with 72,719 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PGNY now has a Market Capitalization of 2224260608 and an Enterprise Value of 1907203712. As of this moment, Progyny’s Price-to-Earnings (P/E) ratio for their current fiscal year is 40.85, and their Forward P/E ratio for the next fiscal year is 26.93. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.00. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.75 while its Price-to-Book (P/B) ratio in mrq is 3.97. Its current Enterprise Value per Revenue stands at 1.503 whereas that against EBITDA is 21.123.
Stock Price History:
The Beta on a monthly basis for PGNY is 0.93, which has changed by 0.5239221 over the last 52 weeks, in comparison to a change of 0.17318606 over the same period for the S&P500. Over the past 52 weeks, PGNY has reached a high of $27.76, while it has fallen to a 52-week low of $14.32. The 50-Day Moving Average of the stock is 10.26%, while the 200-Day Moving Average is calculated to be 14.96%.
Shares Statistics:
The stock has traded on average 1.63M shares per day over the past 3-months and 1575730 shares per day over the last 10 days, according to various share statistics. A total of 86.15M shares are outstanding, with a floating share count of 72.27M. Insiders hold about 16.17% of the company’s shares, while institutions hold 96.69% stake in the company. Shares short for PGNY as of 1765756800 were 5672029 with a Short Ratio of 3.47, compared to 1763078400 on 6677676. Therefore, it implies a Short% of Shares Outstanding of 5672029 and a Short% of Float of 9.090000400000001.
Earnings Estimates
As of right now, 8.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.49, with high estimates of $0.52 and low estimates of $0.46.
Analysts are recommending an EPS of between $1.84 and $1.78 for the fiscal current year, implying an average EPS of $1.81. EPS for the following year is $1.96, with 8.0 analysts recommending between $2.14 and $1.8.
Revenue Estimates
10 analysts predict $306.06M in revenue for. The current quarter. It ranges from a high estimate of $326.32M to a low estimate of $295.87M. As of. The current estimate, Progyny Inc’s year-ago sales were $298.43MFor the next quarter, 10 analysts are estimating revenue of $343.69M. There is a high estimate of $357.81M for the next quarter, whereas the lowest estimate is $330.2M.
A total of 10 analysts have provided revenue estimates for PGNY’s current fiscal year. The highest revenue estimate was $1.3B, while the lowest revenue estimate was $1.27B, resulting in an average revenue estimate of $1.28B. In the same quarter a year ago, actual revenue was $1.17BBased on 10 analysts’ estimates, the company’s revenue will be $1.4B in the next fiscal year. The high estimate is $1.48B and the low estimate is $1.37B.
